United Therapeutics Corporation
https://www.unither.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From United Therapeutics Corporation
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Essential Emerges As A Drug Developer With Renaissance Buy
The acquisition of Renaissance and its promising Phase III-ready asset for neuroblastoma could be the first of a number of deals in the near future, Essential CEO Emma Johnson tells Scrip.
Keeping Up The Pressure In Pulmonary Arterial Hypertension
Merck & Co leads a market expected to exceed $10bn by 2028, but others are aiming to muscle in.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Lung Biotechnology PBC
- Lung Rx, Inc.
- SteadyMed Ltd.
- SteadyMed Therapeutics, Inc.
- Unither Pharmaceuticals
- Unither Virology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice